Characteristics of COVID-19 in patients with multiple sclerosis
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population.
METHODS: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe.
RESULTS: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms.
CONCLUSION: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 57(2022) vom: 01. Jan., Seite 103437 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghadiri, Fereshteh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 18.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2021.103437 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334333644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334333644 | ||
| 003 | DE-627 | ||
| 005 | 20231225223504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2021.103437 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334333644 | ||
| 035 | |a (NLM)34896875 | ||
| 035 | |a (PII)S2211-0348(21)00703-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghadiri, Fereshteh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics of COVID-19 in patients with multiple sclerosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population | ||
| 520 | |a METHODS: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe | ||
| 520 | |a RESULTS: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms | ||
| 520 | |a CONCLUSION: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Iran | |
| 650 | 4 | |a Multiple sclerosis | |
| 700 | 1 | |a Sahraian, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Shaygannejad, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Ashtari, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Ghalyanchi Langroodi, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Baghbanian, Seyed Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Mozhdehipanah, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Majdi-Nasab, Nastaran |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Poursadeghfard, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Beladimoghadam, Nahid |e verfasserin |4 aut | |
| 700 | 1 | |a Razazian, Nazanin |e verfasserin |4 aut | |
| 700 | 1 | |a Ayoubi, Saeideh |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaeimanesh, Nasim |e verfasserin |4 aut | |
| 700 | 1 | |a Eskandarieh, Sharareh |e verfasserin |4 aut | |
| 700 | 1 | |a Naser Moghadasi, Abdorreza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 57(2022) vom: 01. Jan., Seite 103437 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2022 |g day:01 |g month:01 |g pages:103437 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2021.103437 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2022 |b 01 |c 01 |h 103437 | ||